AI in COPD diagnosis can support case finding, spirometry interpretation and equity while GOLD 2026 highlights validation and guideline gaps.
Astegolimab for COPD was evaluated in the ALIENTO and ARNASA trials to assess its efficacy and safety in patients with frequent exacerbations.
Maternal smoking and CC16 are linked to impaired lung development, lung function decline and emphysema progression, increasing lifelong COPD risk.
Expiratory flow-volume curve concavity predicts future respiratory symptoms but shows lower discriminatory accuracy for COPD incidence than FEV1/FVC.
Gut-lung axis microbiome analysis in stable COPD reveals distinct gut and lung microbiomes associated with airflow limitation, exacerbations and ICS use
BMI genetic factors and COPD are associated with decreased emphysema and increased airway wall thickness across quantitative and visual imaging phenotypes
ERS Award Winners 2026 includes Alvar Agustí, who receives the ERS Congress Chair Award from the European Respiratory Society.
2026 GOLD update: key recommendations for primary care on COPD diagnosis, assessment, prevention, treatment, exacerbations and emerging technologies.
2026 GOLD International COPD Conference, November 5–6 in Philadelphia. Discover Session 4 on the diagnosis, assessment and management of COPD.
En este artículo, les presentamos la Conferencia Magistral Manuel Tapia 2018. Dr. Àlvar Agustí García-Navarro. Celebrada en el 51 Congreso Nacional de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR), en Palma de Mallorca, del 31 de mayo al 3 de junio de 2018.
